Zika in Pernambuco: rewriting the first outbreak

Brito, Carlos; Brito, Cecília Coelho Moraes de; Oliveira, Augusto César Penalva de; Rocha, Marília de França; Atanásio, Caio; Asfora, Carolina; Matos, Júlio Dourado; Lima, A. S. N.; Albuquerque, Maria de Fátima Militão de

doi:10.1590/0037-8682-0245-2016

Cited by 31 publications

(30 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ZIKV spread to neighboring States and regions (Brito et al, 2016), reaching most of the Brazilian Northeast, the North, the Midwest, and parts of the Southeast (Cardoso et al, 2015). It did not take long to reach other countries in South (WHO, 2015; Pacheco et al, 2016) and Central America (Lozier et al, 2016), accompanied by an epidemic of GBS cases (Dos Santos et al, 2016) and microcephaly (Cuevas et al, 2016).…”

Section: Emergence and Spread Of Zikv Infectionmentioning

confidence: 99%

Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network

et al. 2017

View full text Add to dashboard Cite

In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV-induced disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations. After describing the make-up of the taskforce, we summarize the emergence of ZIKV in the Americas, Africa and Asia, its spread by mosquitoes, and current control measures. We then review the spectrum of primary ZIKV-induced disease in adults and children, sites of persistent infection and sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome, including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. After reviewing current understanding of the mechanisms of emergence of Zika virus, we consider the likely future of the pandemic.

show abstract

Section: Emergence and Spread Of Zikv Infectionmentioning

confidence: 99%

Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In Pernambuco, also in northeastern Brazil and another epicenter of the epidemic as well as of neurological complications, the official registries of the surveillance system reported dengue fever as the arboviral disease responsible for most cases of the epidemic (>140,000) and <2,000 suspected Zika cases. However, a hospital-based study in the state capital analyzed 1,046 records of suspected cases of arboviruses, classifying 84% of them as probable cases of Zika and only 14% as dengue, based on clinical criteria (11).…”

Section: Editorialmentioning

confidence: 99%

Evidence of an association between neurological manifestations (microcephaly and GBS) and Zika virus infection: the usefulness of ecological studies with syndromic surveillance data

Brasil¹,

Wakimoto²,

Brito³

2017

J Public Health Emerg

View full text Add to dashboard Cite

“…There is no treatment available for ZIKV infection, thus the current state‐of‐the science for ZIKV disease management is centered on public health interventions to limit disease transmission to vulnerable populations and to provide supportive care for newborns and infants with congenital malformations and developmental abnormalities requiring prolonged allocation of finite health care resources . Furthermore, the implications for blood product safety and maternal, child and reproductive health highlight the cross‐cutting nature of ZIKV disease and yet again reveal deficiencies in international preparedness and capacity to respond to biologic threats.…”

Section: Introductionmentioning

confidence: 99%

“…3 For example, the incidence rates (per 100 000 population) reported in the Americas from 2015 to 2018 for ZIKV disease and the number of live newborns who met the criteria for suspected congenital syndrome associated with ZIKV infection were 0.06 and 103 in North America, 176.1 and 2952 in Brazil, and 411.0 and 27 in non-Latin Caribbean countries. 4 There is no treatment available for ZIKV infection, 3 thus the current state-of-the science for ZIKV disease management is centered on public health interventions to limit disease transmission to vulnerable populations and to provide supportive care for newborns and infants with congenital malformations and developmental abnormalities [5][6][7][8] requiring prolonged allocation of finite health care resources. 9,10 Furthermore, the implications for blood product safety and maternal, child and reproductive health highlight the cross-cutting nature of ZIKV disease and yet again reveal deficiencies in international preparedness and capacity to respond to biologic threats.…”

Section: Introductionmentioning

confidence: 99%

An evaluation of WHO emergency guidelines for Zika virus disease

Norris

Louis

Sawin

et al. 2019

J Evidence Based Medicine

View full text Add to dashboard Cite

Background In the face of an unclear causal association between Zika virus in utero exposure and congenital abnormalities and urgent demand for guidance, the World Health Organization (WHO) had to produce timely and trustworthy guidelines during the 2016 Public Health Emergency of International Concern (PHEIC). Methods This is a cross‐sectional evaluation of WHO emergency guidelines produced during the Zika virus disease PHEIC from 1 February to 18 November 2016. We assessed adherence to WHO publication requirements and the reporting of guideline development processes associated with trustworthiness. In the absence of quality appraisal tools for guidelines developed under compressed timeframes, we applied the Appraisal of Guidelines for Research and Evaluation (AGREE II) tool. Results We included 21 guidelines (13 de novo and 8 updates). Six guidelines used a formal evidence review process. Most guidelines involved external experts in the development process and collected declarations of interest. Peer review was reported in six documents. Most emergency guidelines included updating plans. The highest scoring AGREE II domain was clarity of presentation (median score 78%); the lowest scoring domain was applicability (median score 18%). Conclusion WHO developed moderate‐ to high‐quality emergency guidelines in the challenging context of a PHEIC. We found improvement opportunities for WHO guideline development teams in the use of evidence to formulate recommendations, the collection of declarations of interest, reporting of conflicts of interest, and the use of existing WHO organizational quality assurance processes.

show abstract

Zika in Pernambuco: rewriting the first outbreak

Cited by 31 publications

References 12 publications

Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network

Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network

Evidence of an association between neurological manifestations (microcephaly and GBS) and Zika virus infection: the usefulness of ecological studies with syndromic surveillance data

An evaluation of WHO emergency guidelines for Zika virus disease

Contact Info

Product

Resources

About